Wallace, Owen, Arrowsmith, John, Leach, Andrew, Leeson, Paul, Mandrell, Sam, Owen, Robert, Pairaudeau, Garry, Pennie, William, Pickett, Stephen, Wang, Jibo, Waring, Michael and Weir, Alex (2015) A comprehensive analysis of development attrition in drug candidates from four major pharmaceutical companies. Nature Reviews Drug Discovery.

Abstract

A compilation of attrition data for oral development compounds nominated by four large pharmaceutical companies (AstraZeneca, Eli Lilly, GlaxoSmithkline and Pfizer) in the period 2000 to 2010 has been carried out. It was anticipated that pooling data would help to minimize any issues of inter-company variability as described above and that the larger dataset would increase the chances of observing meaningful relationships. Here, the nature of this compiled dataset and an analysis of the causes of attrition, with a focus on toxicology and safety, are described. The links between these observations and the physical properties of the drug candidates are assessed

Item Type:	Article
Date Deposited:	26 Apr 2016 23:45
Last Modified:	26 Apr 2016 23:45
URI:	https://oak.novartis.com/id/eprint/22853